Evidence of quality of life for hospitalised patients with COVID-19: a scoping review

Edward JD Webb, Natalie King, Daniel Howdon, Enitan D Carrol, Joanne Euden, Philip Howard, Philip Pallmann, Martin J Llewelyn, Emma Thomas-Jones, Bethany Shinkins, and Jonathan Sandoe; on behalf of the Procalcitonin: Evaluation of Antibiotic use in COVID-19 Hospitalised Patients (PEACH) Study Team

1Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
2Department of Clinical Infection Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
3Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK
4School of Healthcare, Faculty of Medicine and Health, University of Leeds, Leeds, UK
5Department of Medicines Management and Pharmacy, Leeds Teaching Hospitals, Leeds General Infirmary, Leeds, UK
6Brighton and Sussex Medical School, University of Sussex and University Hospitals Sussex NHS Foundation Trust, Brighton, UK
7Division of Health Sciences, Warwick Medical School, University of Warwick, Warwick, UK
8Healthcare Associated Infection Group, Leeds Institute of Medical Research, School of Medicine, University of Leeds, Leeds, UK
9Leeds Teaching Hospitals NHS Trust, Leeds, UK

*Corresponding author e.j.d.webb@leeds.ac.uk
†Joint last authors

Published May 2024
DOI: 10.3310/ATPR4281

Plain language summary

Evidence of quality of life for hospitalised patients with COVID-19: a scoping review

Health Technology Assessment 2024
DOI: 10.3310/ATPR4281

NIHR Journals Library www.journalslibrary.nihr.ac.uk

This article should be referenced as follows:
Plain language summary

Quality of life can be measured using short, simple surveys. It is important to assess quality of life in this way, as it can show how health conditions affect people. Quality-of-life surveys can also be used to measure how treatments benefit people and to judge whether it is cost-effective to fund them. COVID-19 is a new disease, with new treatments developed to treat it. COVID-19 also created possible barriers to collecting quality-of-life survey data, especially from people in hospital at the start of the pandemic.

This paper reviews studies which report data on quality of life for people hospitalised with COVID-19, especially how much evidence is available and how the studies were carried out.

There were 35 studies included in the review. Of these, 13 assessed how cost-effective treatments for COVID-19 were. None of them collected survey responses directly from patients. Instead, they used data previously collected from people with other conditions such as influenza to represent people with COVID-19’s quality of life. The studies which did collect data from patients used a wide variety of different surveys, which made comparing their results difficult. Mental health-related surveys were used by 12 studies, and a further 12 used sleep-related surveys. Relatively few studies used general surveys which could assess the overall effect of COVID-19 on people’s quality of life.

In future health crises, we recommend using more general quality-of-life measures. We also recommend that researchers co-ordinate to reduce the number of different surveys they use, as this will make comparing results easier.